Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8835 in Advanced Solid Tumours
NCT02260661Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of AZD8835 in solid malignancy and breast cancer (4 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Tolerated Dose or Recommended Phase II Dose and Safety and Tolerability Profile up to 36 months. Started Nov 2014; status: completed.
02
Drugs
AZD8835
03
Conditions
solid malignancybreast cancer
Beyond the preview
Go deeper on NCT02260661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260661.